Biostem Technologies (BSEM) Company presentation summary

Company overview and market positioning

• Focuses on perinatal tissue-based regenerative therapies for surgical and advanced wound care applications.

• Operates manufacturing in Pompano Beach, FL, with headquarters in Ft Lauderdale.

• FY 2026 revenue guidance is $26–29M, with a market capitalization of $57M as of August 2026.

• Holds a broad, clinically differentiated, and patent-protected product portfolio with over 10 products.

• Addresses a $26B total addressable market in US surgical and chronic wound applications.

Growth strategy and recent acquisition

• Acquisition of BioTissue expanded the product portfolio and diversified the customer base.

• Shifted focus from wound-centric, CMS-dependent sales to surgical-centric, hospital-based markets.

• Gained access to hospitals, ambulatory surgery centers, and VA/DoD facilities.

• Expanded salesforce to 60+ reps, leveraging GPO and IDN contracts for broader market access.

• Manufacturing tech transfer planned for 2027 to improve margins through vertical integration.

Product portfolio and clinical evidence

• Offers three platform technologies: BioRetain, SteriTek, and CryoTek, with dry, hydrated, and cryopreserved products.

• Portfolio covers chronic wound care, orthopedics, foot & ankle, urology, colorectal, and spine applications.

• Over 400 publications support clinical efficacy, with more than 1.2M product applications.

• Near-term evidence agenda includes publishing DFU and VLU data and expanding real-world evidence.

• Clinical data shows improved outcomes and reduced costs in procedures like robot-assisted radical prostatectomy.